Primidone
Brand names: Mysoline, Primidone
At a glance
- Medicare prescriptions, 2024
- 1,074,694
- Medicare drug cost
- $28.5M
- Average cost per prescription
- $26.56
- Clinicians who prescribed it
- 31,840
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
MYSOLINE, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 39.2%
- Family Medicine 19.7%
- Internal Medicine 16.5%
- Nurse Practitioners 14.2%
- Physician Assistants 4.6%
- Geriatric Medicine 1.5%
- General Practice 0.9%
- Psychiatry 0.4%
- Hospitalist 0.4%
- Physical Medicine & Rehabilitation (PM&R) 0.4%
- Sleep Medicine 0.3%
- Child Neurology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 16% from 2019 to 2024.
Biggest change by state since 2019
- Kansas +35%
- Oklahoma +31%
- Arkansas +30%
- Utah +30%
- Connecticut +27%
- California (smallest change) +5%
- New York (smallest change) +7%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Actavis Pharma, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | white round tablet, 10 mm, scored to split in 2 | DAN DAN 5321 |
Bausch Health US, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white square tablet, 6 mm, scored to split in 2 | MYSOLINE 50 M |
| 250 mg | yellow square tablet, 10 mm, scored to split in 2 | MYSOLINE 250 M |
Ncs Healthcare of Ky, LLC dba Vangard Labs
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm, scored to split in 2 | 684 O |
Oxford Pharmaceuticals, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm, scored to split in 2 | 684 O |
| 250 mg | yellow round tablet, 10 mm, scored to split in 2 | 685 O |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm, scored to split in 2 | 684 O |
| 250 mg | yellow round tablet, 10 mm, scored to split in 2 | 685 O |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Jun 2026 · Amneal Pharmaceuticals, LLC · Class III
Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer. - Apr 2026 · Amerisource Health Services LLC · Class III
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API. - Apr 2026 · Golden State Medical Supply Inc. · Class III
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API. - Apr 2026 · Lannett Company Inc. · Class III
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.